http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2010120724-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-41 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-69 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 |
| filingDate | 2008-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2010120724-A |
| titleOfInvention | COMBINED THERAPY BY ANTIBODIES ANTI-CD20 TYPE II IN COMBINATION WITH AN INHIBITOR PROTEAS |
| abstract | 1. The use of anti-CD20 type II antibodies for the manufacture of a medicament for the treatment of cancer expressing CD20 in combination with a proteasome inhibitor. ! 2. The use of anti-CD20 type II antibodies for the manufacture of a medicament for the treatment of a patient suffering from cancer expressing CD20 in combination with a proteasome inhibitor. ! 3. The use according to claim 1, characterized in that the proteasome inhibitor is characterized by anti-proteasome inhibitory activity with an IC50 value of 5 μM or less. ! 4. The use according to claim 1, characterized in that the ratio of the binding activities of the indicated anti-CD20 type II antibodies and rituximab against CD20 on Raji cells (ATCC No. CCL-86) is from 0.3 to 0.6. ! 5. The use according to claim 1, characterized in that said anti-CD20 type II antibodies are humanized B-Ly1 antibodies. ! 6. The use according to claim 5, characterized in that said anti-CD20 type II antibodies have increased antibody-dependent cell-mediated cytotoxicity (ASCOT). ! 7. The use according to claim 5, characterized in that at least 40% or more of the oligosaccharides in the Fc region of said anti-CD20 type II antibodies are unfucosylated. ! 8. The use according to claim 7, characterized in that said proteasome inhibitor is selected from the group consisting of peptide aldehydes, leptide boronates, peptide epoxyketones or A. salinosporamide! 9. The use according to claim 7, characterized in that said proteasome inhibitor is bortezomib. ! 10. The use according to claim 9, characterized in that the patient is administered one or more other additional cytotoxic, chemotherapeutic or antitumor agents, or compounds that |
| priorityDate | 2007-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 25.